Clarithromycin in treatment of early Lyme disease: A pilot study

Raymond J. Dattwyler; Edgar Grunwaldt; Benjamin J. Luft

doi:10.1128/aac.40.2.468

Clarithromycin in treatment of early Lyme disease: A pilot study

Raymond J. Dattwyler
, Edgar Grunwaldt
, Benjamin J. Luft

Infectious Diseases

Stony Brook University

Stony Brook University

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Forty-one patients with erythema migrans were enrolled in an open- labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.

Original language	English
Pages (from-to)	468-469
Number of pages	2
Journal	Antimicrobial Agents and Chemotherapy
Volume	40
Issue number	2
DOIs	https://doi.org/10.1128/aac.40.2.468
State	Published - Feb 1996

Access to Document

10.1128/aac.40.2.468

Cite this

@article{ea0724789cab4934bd62d925858a6320,

title = "Clarithromycin in treatment of early Lyme disease: A pilot study",

abstract = "Forty-one patients with erythema migrans were enrolled in an open- labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91\% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.",

author = "Dattwyler, \{Raymond J.\} and Edgar Grunwaldt and Luft, \{Benjamin J.\}",

year = "1996",

month = feb,

doi = "10.1128/aac.40.2.468",

language = "English",

volume = "40",

pages = "468--469",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "2",

}

TY - JOUR

T1 - Clarithromycin in treatment of early Lyme disease

T2 - A pilot study

AU - Dattwyler, Raymond J.

AU - Grunwaldt, Edgar

AU - Luft, Benjamin J.

PY - 1996/2

Y1 - 1996/2

N2 - Forty-one patients with erythema migrans were enrolled in an open- labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.

AB - Forty-one patients with erythema migrans were enrolled in an open- labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.

UR - https://www.scopus.com/pages/publications/0030048104

U2 - 10.1128/aac.40.2.468

DO - 10.1128/aac.40.2.468

M3 - Article

C2 - 8834900

SN - 0066-4804

VL - 40

SP - 468

EP - 469

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 2

ER -

Clarithromycin in treatment of early Lyme disease: A pilot study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this